UK life sciences partnership to use AI in disease detection

The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence (AI) to detect diseases at an early stage.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

NHS to receive £250m for new AI lab

8 August 2019 The NHS will receive a £250 million investment to develop a new National AI Lab, which will use the technology to improve patient health, the UK government has announced.

Big Pharma

EU invests €35m into AI cancer diagnostics

10 July 2019 The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.

Big Pharma

NHS partners with drugmakers to eliminate hep C

3 May 2019 The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

UK life sciences partnership to use AI in disease detection

More on this story

Editor's picks

Editor's picks

More features